Paper7987997
A phase I/II study of 4'-O-tetrahydropyranyl-doxorubicin, 5-fluorouracil, and high-dose leucovorin as first-line therapy in advanced breast cancer patients.
Stöger H and 9 others. Cancer Chemother Pharmacol, 1994. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. A phase I/II study of 4'-O-tetrahydropyranyl-doxorubicin, 5-fluorouracil, and high-dose leucovorin as first-line therapy in advanced breast cancer patients. Papers, record 7987997. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7987997
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Breast Neoplasms | Major topic |
| Doxorubicin | Major topic |
| Fluorouracil | Major topic |
| Leucovorin | Major topic |
| Adult | |
| Aged | |
| Diarrhea | |
| Drug Administration Schedule | |
| Female | |
| Humans | |
| Leukopenia | |
| Middle Aged | |
| Nausea |
Source PubMed
References19
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 6341335 | Chemotherapy of breast cancer: current views and results. | Int J Radiat Oncol Biol Phys | 1983 | https://conductscience.org/library/papers/6341335 | PubMed |
| 2 | 496103 | Risk factors for doxorubicin-induced congestive heart failure. | Ann Intern Med | 1979 | https://conductscience.org/library/papers/496103 | PubMed |
| 3 | 2369794 | 4'-O-tetrahydropyranyl-doxorubicin in advanced breast cancer: a phase II study. | Cancer Chemother Pharmacol | 1990 | https://conductscience.org/library/papers/2369794 | PubMed |
| 4 | 3517242 | Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. | J Clin Oncol | 1986 | https://conductscience.org/library/papers/3517242 | PubMed |
| 5 | 3963850 | [Phase II study of (2''R)-4'-O-tetrahydropyranyladriamycin (THP) in patients with solid tumors. Multi-Institutional Cooperative Study]. | Gan To Kagaku Ryoho | 1986 | https://conductscience.org/library/papers/3963850 | PubMed |
| 6 | 528373 | Tetrahydropyranyl derivatives of daunomycin and adriamycin. | J Antibiot (Tokyo) | 1979 | https://conductscience.org/library/papers/528373 | PubMed |
| 7 | 3501543 | Preliminary results of a phase II trial for the treatment of metastatic breast cancer with 5-fluorouracil and leucovorin. | NCI Monogr | 1987 | https://conductscience.org/library/papers/3501543 | PubMed |
| 8 | 3874000 | Treatment of advanced breast cancer with 5-fluorouracil and high-dose folinic acid: preliminary results. | Chemioterapia | 1985 | https://conductscience.org/library/papers/3874000 | PubMed |
| 9 | 6424579 | [Chemical modification of anticancer agents from viewpoints of their pharmacokinetics]. | Gan To Kagaku Ryoho | 1984 | https://conductscience.org/library/papers/6424579 | PubMed |
| 10 | 3162456 | Phase I study of pirarubicin. | J Cancer Res Clin Oncol | 1988 | https://conductscience.org/library/papers/3162456 | PubMed |
| 11 | 7049347 | Comparison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group Trial. | Cancer | 1982 | https://conductscience.org/library/papers/7049347 | PubMed |
| 12 | 2443619 | A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. | J Clin Oncol | 1987 | https://conductscience.org/library/papers/2443619 | PubMed |
| 13 | 3947112 | [A phase II study of (2''R)-4'-0-tetrahydropyranyladriamycin (THP) in patients with hematological malignancies. THP Study Group]. | Gan To Kagaku Ryoho | 1986 | https://conductscience.org/library/papers/3947112 | PubMed |
| 14 | 3547667 | New agents and new medical treatments for advanced breast cancer. | Semin Oncol | 1987 | https://conductscience.org/library/papers/3547667 | PubMed |
| 15 | 1107570 | Adriamycin-a review. | J Natl Cancer Inst | 1975 | https://conductscience.org/library/papers/1107570 | PubMed |
| 16 | 2661735 | Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. | J Clin Oncol | 1989 | https://conductscience.org/library/papers/2661735 | PubMed |
| 17 | 912660 | Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. | Cancer | 1977 | https://conductscience.org/library/papers/912660 | PubMed |
| 18 | 6985698 | Cancer of the breast: the past decade (first of two parts). | N Engl J Med | 1980 | https://conductscience.org/library/papers/6985698 | PubMed |
| 19 | 3954376 | [Pharmacokinetic studies of THP-ADM (tetrahydropyranyl adriamycin)]. | Gan To Kagaku Ryoho | 1986 | https://conductscience.org/library/papers/3954376 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/7987997
GET https://conductscience.org/api/papers/v1/7987997/authors